Neumora Therapeutics (NMRA) Cash from Operations (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly Cash from Operations came in at 46404000.0 in Q1 2026, up 21.94% year-on-year from 38054198.97 in Q1 2025, and up 3.23% quarter-over-quarter from 47955000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Cash from Operations (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 46404000.0 for Q1 2026.
- On a quarterly basis, Cash from Operations rose 21.94% year-over-year to 46404000.0 in Q1 2026; TTM through Mar 2026 was 193396000.0, a 3.03% increase from a year earlier, with the FY2025 full-year figure at 206440000.0, down 12.85% from the prior year.
- Cash from Operations grew to 46404000.0 in Q1 2026 per NMRA's latest filing, from 47955000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 30366000.0 in Q4 2022 and bottomed at 59448000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 47203000.0 (2023), against an average of 44958857.14.
- Biggest YoY gain for Cash from Operations was 29.91% in 2024; the steepest drop was 81.03% in 2024.
- Year by year, Cash from Operations stood at 30366000.0 in 2022, then sank by 69.41% to 51442000.0 in 2023, then rose by 2.14% to 50340000.0 in 2024, then advanced by 4.74% to 47955000.0 in 2025, then increased by 3.23% to 46404000.0 in 2026.
- Per Business Quant, the three latest NMRA Cash from Operations figures stand at 46404000.0 (Q1 2026), 47955000.0 (Q4 2025), and 46633000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - | -46.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.40 Mn |
| Mar 31, 2026 | -46.40 Mn |
| Dec 31, 2025 | -47.96 Mn |
| Dec 31, 2025 | -47.96 Mn |
| Sep 30, 2025 | -46.63 Mn |
| Sep 30, 2025 | -46.63 Mn |
| Jun 30, 2025 | -52.40 Mn |
| Jun 30, 2025 | -52.40 Mn |
| Mar 31, 2025 | -59.45 Mn |
| Mar 31, 2025 | -59.45 Mn |
| Dec 31, 2024 | -50.34 Mn |
| Dec 31, 2024 | -50.34 Mn |
| Sep 30, 2024 | -33.48 Mn |
| Sep 30, 2024 | -33.48 Mn |
| Jun 30, 2024 | -56.16 Mn |
| Jun 30, 2024 | -56.16 Mn |
| Mar 31, 2024 | -42.96 Mn |
| Mar 31, 2024 | -42.96 Mn |
| Dec 31, 2023 | -51.44 Mn |
| Dec 31, 2023 | -51.44 Mn |